COMP <GO>
CRL vs UNH // ENTERPRISE SCALE & MARKET CAP
Charles River Laboratories International Inc. (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: CRL 2
— UNH 11
▲ ENTERPRISE SCALE & MARKET CAP LEADER: UNH
LAST: $351.87 (+3.94%) • MKT CAP: $16.16B
market-cap
$16.16B
LAST: $404.44 (+1.00%) • MKT CAP: $359.43B
market-cap
$359.43B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRL VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRL | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.31% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 0.40% | 12.38% | -11.98 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 15.3x | +79.73 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 3.10% | 6.25% | -3.15 | UNH | /fcf-yield <GO> |
| Operating Margin | 0.60% | 5.32% | -4.72 | UNH | /operating-margins <GO> |
| Net Profit Margin | -3.60% | 3.53% | -7.13 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | -0.90% | 3.33% | -4.23 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.65 | 3.09 | +0.56 | CRL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.2 | 55.1 | -2.90 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.33 | +0.82 | CRL | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.0x | 17.7x | +5.26 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $16.16B | $359.43B | -$343.27B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRL REV | UNH REV | CRL GROSS % | UNH GROSS % | CRL FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.02B | $447.57B | — | 88.7% | $557.0M | $16.07B |
| FY 2024 | $4.05B | $400.28B | — | 88.3% | $552.3M | $20.70B |
| FY 2023 | $4.13B | $371.62B | — | 89.6% | $498.1M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRL // BETA 1.15
UNH // BETA 0.33